150th implant, page-36

pc_75u....please don't be so aggressive..... "What makes your opinion valid?"

I would ask, what makes anyone's opinion valid on this board? Please give me some respect. Anyway, for the record i hold a Master's degree in Health Science but i have no formal training in heart disease surgery or stem cell therapy.

I did qualify my comparison of HTW and VCR that it was based on implant rate alone. I agree that according to regulatory approvals then HTW are not as far behind. But that is assuming they can meet their schedule. Note i had not read HTWs recent announcement at the time of my post. Also i didn't say that size doesn't matter, i said i thought it was significantly overrated. I gave my reasons. If you don't like them then that is fine. The deciding factors on best product i think will be effectiveness, patient comfort and low adverse event rate. Anyway, good luck to you if you hold HTW.

As for stem cells. From Wikipedia: "Several clinical trials targeting heart disease have shown that adult stem cell therapy is safe. However, none of these trials have proven efficacy."

Normal drug may be up to 10 yrs to commercialisation AFTER we have a working product. Stem cells are much more complex due to their administration and other problems outlined below. Also there is no proof that stem cells even work yet for heart disease, let alone the long lead time for regulatory approvals, clinical trials etc to deliver to the market. Actually can i change my original estimate from 10-20 yrs to 30 yrs? lol......yes you're right i am no expert in this area but if you disagree with me then that is fine. As i said, it is only my opinion.

Also from Wikipedia:

"After 20 years of research, there are no approved treatments or human trials using embryonic stem cells. Their tendency to produce tumors and malignant carcinomas, cause transplant rejection, and form the wrong kinds of cells are just a few of the hurdles that embryonic stem cell researchers still face.[12]"


And for adult stem cells:
"many technical difficulties remain which hinder the ultimate goals in adult stem cell therapeutics. Expanding adult stem cell populations extracted from patients remains a large problem. Also, even once these populations are expanded, implanted stem cells may not expand or grow efficiently enough to add enough corrective factor to be beneficial for treatment. These and other technical problems remain to be solved.
"